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Abstract
Background: Approximately 50 % of gastric adenocarcinomas belong to a molecular subgroup characterised by
chromosomal instability and a strong association with the intestinal histological subtype. This subgroup typically
contains alterations in the receptor tyrosine kinase–RAS pathway, for example EGFR or HER2 gene amplifications
leading to protein overexpression. In clinical practice, HER2 overexpressing metastatic gastric cancer is known to
respond to treatment with anti-HER2 antibodies. By contrast, anti-EGFR antibodies have not been able to provide
survival benefit in clinical trials, which, however, have not included patient selection based on the histological
subtype or EGFR gene copy number analysis of the tumours. To examine the role of EGFR as a potential biomarker,
we studied the prevalence, clinicopathological associations as well as prognostic role of EGFR and HER2 expression
and gene amplification in intestinal adenocarcinomas of the stomach, gastro-oesophageal junction and distal
oesophagus.
Methods: Tissue samples from 220 patients were analysed with EGFR and HER2 immunohistochemistry. Those
samples with moderate/strong staining intensity were further analysed with silver in situ hybridization to quantify
gene copy numbers. The results were associated with clinical patient characteristics and survival.
Results: Moderate/strong EGFR protein expression was found in 72/220 (32.7 %) and EGFR gene amplification in
31/220 (14.1 %) of the tumours, while moderate/strong HER2 protein expression was detected in 31/220 (14.1 %)
and HER2 gene amplification in 29/220 (13.2 %) of the tumours. EGFR and HER2 genes were co-amplified in eight
tumours (3.6 %). EGFR gene amplification was more common in tumours of distal oesophagus/gastro-oesophageal
junction/cardia than in those of gastric corpus (p = 0.013). It was associated with shortened time to cancer
recurrence (p = 0.026) and cancer specific survival (p = 0.033).
Conclusions: EGFR gene amplification is relatively common in intestinal adenocarcinomas and associates with
decreased survival. It is rarely concurrent with HER2 gene amplification, suggesting that anti-EGFR therapies might
be applicable to some patients not eligible for anti-HER2 treatment. Analogous to HER2 testing, determination of
EGFR gene amplification status in concert with immunohistochemistry could improve the specificity of patient
selection when investigating the possible benefits of anti-EGFR therapies in the treatment of gastric adenocarcinomas.
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Background
EGFR (ERBB1) and HER2 (ERBB2) are members of a
tyrosine kinase receptor family frequently activated in
cancer either by receptor overexpression or mutations.
Metastatic HER2 overexpressing gastric or gastro-
oesophageal junction (GOJ) adenocarcinomas can be
treated with monoclonal anti-HER2 antibodies in combin-
ation with chemotherapy and the only targeted first-line
antibody therapy for these tumours is trastuzumab. In
contrast, monoclonal anti-EGFR antibodies are currently
not indicated for the treatment of gastric cancer, although
they are used for patients with metastatic colorectal or
head and neck carcinomas.
Gastric adenocarcinomas are traditionally divided into
intestinal and diffuse histological subtypes by Laurén
classification [1]. Interestingly, it was recently suggested
that these tumours can be classified into four distinct
molecular subgroups based on their genomic alterations.
One of the subgroups, characterised by chromosomal
instability (CIN), accounts for about 50 % of gastric
cancers and is strongly associated with the intestinal
histological subtype and GOJ/cardiac location. Typical
alterations in the CIN subtype include TP53 gene aberra-
tions and activation of the receptor tyrosine kinase–RAS
pathway, for example by receptor tyrosine kinase gene
amplifications. In contrast, diffuse-type tumours are
concentrated in a separate subgroup associating with
overall genomic stability as well as distinctive genetic
changes affecting cell adhesion and motility [2].
While anti-EGFR antibody treatment is beneficial in
colorectal cancer [3, 4], no survival benefit has been ob-
served in phase III clinical trials on gastric and gastro-
oesophageal cancer for patients treated with anti-EGFR
antibody-chemotherapy combination compared with pa-
tients treated with chemotherapy alone [5, 6]. Importantly,
however, these studies included no patient selection based
on the histological subtype of the tumours, EGFR protein
expression or EGFR gene copy number (GCN) analysis.
As demonstrated in the case of anti-HER2 therapy, an ap-
propriate preselection with an easily applicable biomarker
test might increase the potential to identify those patients
who could benefit from anti-EGFR therapy.
In this study, we focused on intestinal adenocarcinomas
in three locations: the stomach, gastro-oesophageal junc-
tion and distal oesophagus. Our aim was to examine the
prevalence, clinicopathological associations as well as prog-
nostic role of EGFR and HER2 protein expression and gene
amplification in these tumours. First, we analysed EGFR
and HER2 alterations by using immunohistochemistry
(IHC) to select the tumours with moderate/strong expres-
sion of EGFR or HER2 protein. Second, we performed
EGFR or HER2 silver in situ hybridisation (SISH) in se-
lected cases to quantify GCNs. The validity of this algo-
rithm for EGFR gene has previously been demonstrated
with colorectal adenocarcinomas [7, 8] and was confirmed
in this study by a set of control samples with negative or
weak IHC staining.
Methods
Patients and clinical tumour material
The study population in this retrospective study consists
of 220 patients diagnosed with intestinal adenocarcinoma
of the stomach, gastro-oesophageal junction or distal
oesophagus at the Turku University Hospital between the
years 1993 and 2012. Initially, we used the clinical data-
base of Auria Biobank (see below) to find all patients with
the diagnosis of adenocarcinoma of the stomach, gastro-
oesophageal junction or distal oesophagus (n = 437). The
original histopathological information regarding these
samples was then obtained to compile a preliminary list of
patients, and the respective histological slides were re-
trieved from the archive. The exclusion criteria for this
study were: diffuse or neuroendocrine histological subtype
(n = 155), metastatic adenocarcinoma from a different
organ (n = 6), intramucosal carcinoma (Tis) (n = 23) and
insufficient sample material (n = 33). All cases were reana-
lysed by an expert gastrointestinal pathologist and the in-
testinal histological subtype of the tumours was confirmed
by the presence of well-defined glandular structures in
accordance with the Laurén classification [1]. Primarily,
tissue samples from primary surgical specimens were
included. In order to attain a comprehensive study
population, representative biopsies were used in case of
22 patients (10 %): four (1.8 %) patients were not operated
due to stage IV disease at the time of diagnosis and 18
(8.2 %) patients had received perioperative chemoradio-
therapy resulting in insufficient surgical material for immu-
nohistochemical analysis. The type of surgery was total
gastrectomy for 120 (54.5 %) patients, subtotal gastrectomy
or tumour resection for 79 (35.9 %) patients and palliative
surgery for 17 (7.7 %) patients. The residual tumour classi-
fication was determined as R0 (no residual tumour) for
167 (75.9 %) patients, R1 (microscopic residual tumour)
for 24 (10.9 %) patients and R2 (macroscopic residual)
for 17 (7.7 %) patients. The residual tumour status
could not be determined for 12 (5.5 %) patients. The
median follow-up time for all patients was 10.5 years.
The patient characteristics are presented in Table 1.
Tumour stage was assessed according to the current
WHO Classification manual [9]. The study was con-
ducted in accordance with the Declaration of Helsinki
and the Finnish legislation for the use of archived tissue
specimens and associated clinical information. The clin-
ical data were retrieved, and the histological samples
were collected and analysed with the endorsement of the
National Authority for Medico-Legal Affairs and The
Ethics Committee of the Hospital District of Southwest
Finland as well as with the permission of Auria Biobank
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Table 1 Patient characteristics
Female, N (%) Male, N (%) All, N (%)
Number of patients 79 (35.9) 141 (64.1) 220
Age at diagnosis (years)
Median 77 72 74
Range 33–93 43–90 33–93
Site of primary tumour
Distal oesophagus 4 (5.1) 16 (11.3) 20 (9.1)
GOJ/cardia 17 (21.5) 46 (32.6) 63 (28.6)
Corpus 21 (26.6) 44 (31.2) 65 (29.5)
Antrum/pylorus 37 (46.8) 35 (24.8) 72 (32.7)
Tumour differentiation grade
Grade 1 14 (17.7) 16 (11.3) 30 (13.6)
Grade 2 33 (41.8) 70 (49.6) 103 (46.8)
Grade 3 32 (40.5) 55 (39.0) 87 (39.5)
Stage at diagnosis
IA 15 (19.0) 18 (12.8) 33 (15.0)
IB 7 (8.9) 19 (13.5) 26 (11.8)
IIA 17 (21.5) 33 (23.4) 50 (22.7)
IIB 14 (17.7) 19 (13.5) 33 (15.0)
IIIA 7 (8.9) 21 (14.9) 28 (12.7)
IIIB 11 (13.9) 19 (13.5) 30 (13.6)
IIIC 1 (1.3) 5 (3.5) 6 (2.7)
IV 7 (8.9) 7 (5.0) 14 (6.4)
Residual tumour classification
R0 (no residual tumour) 62 (78.5) 105 (74.5) 167 (75.9)
R1 (microscopic residual tumour) 5 (6.3) 19 (13.5) 24 (10.9)
R2 (macroscopic residual tumour) 8 (10.1) 9 (6.4) 17 (7.7)
Rx (unknown) 4 (5.1) 8 (5.7) 12 (5.5)
Perioperative and adjuvant therapya (N = 206)
Only chemotherapy 7 (9.7) 24 (17.9) 31 (15.0)
Chemoradiotherapy 4 (5.6) 16 (11.9) 20 (9.7)
Only radiation therapy 1 (1.4) 4 (3.0) 5 (2.4)
No adjuvant therapy 58 (80.6) 89 (66.4) 147 (71.4)
Unknown 2 (2.8) 1 (0.7) 3 (1.5)
Tumour recurrenceb(N = 195)
No recurrence 55 (79.7) 82 (65.1) 137 (70.3)
Single metastasis >6 months 10 (14.5) 26 (20.6) 36 (18.5)
Multiple metastases >6 months 4 (5.8) 18 (14.3) 22 (11.3)
Follow-up status
Alive and free of disease 22 (27.8) 31 (22.0) 53 (24.1)
Alive with disease 1 (1.3) 1 (0.7) 2 (0.9)
Died of disease 43 (54.4) 74 (52.5) 117 (53.2)
Died of other cause 12 (15.2) 30 (21.3) 42 (19.1)
Unknown cause of death 1 (1.3) 5 (3.5) 6 (2.7)
GOJ gastro-oesophageal junction
aExcluding stage IV, bExcluding stage IV and recurrence <6 months
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hosting the specimen archive. All the specimens were
from Auria biobank, which has obtained its archived
diagnostic sample collection with an opt-out procedure
according to the Finnish biobank act [10]. Biobanks autho-
rized and inspected by National Supervisory Authority for
Welfare and Health can provide human specimens col-
lected during diagnostic procedures and associated clinical
information for research purposes based on the biobank’s
scientific board review. Thus, informed consent from sur-
viving patients was not required.
Procedures
For each tumour, the most representative formalin-fixed
paraffin-embedded (FFPE) tissue block was chosen and
new sections were cut for both IHC staining and SISH.
The methods for EGFR IHC and EGFR SISH have been
described previously [7], and HER2 IHC was performed
similarly with monoclonal HER2 antibody (clone 4B5,
Ventana Medical Systems/Roche Diagnostics, Tucson,
AZ, USA). HER2/Chr17 double-SISH was detected with
HER2 DNA Probe and INFORM Chromosome 17 Probe
(Ventana/Roche) and performed with ultraView SISH
Detection Kit and ultraView Alkaline Phosphatase (AP)
Red ISH Detection Kit (Ventana/Roche).
Immunohistochemistry and silver in situ hybridization
With EGFR, tumour scoring was based on the most in-
tense membranous or membranous + cytoplasmic staining
(0, negative; 1+, weak; 2+, moderate; 3+, strong). Strong
staining was seen as intense reaction with 5x objective
magnification, moderate staining was clearly identified
with 5x objective magnification and weak staining was
identified only with 10x objective magnification. Spec-
imens were classified as IHC high if showing 2+ or 3+
membranous or membranous + cytoplasmic staining
intensity in ≥10 % of tumour cells in surgical specimens or
in ≥5 clustered tumour cells in biopsies. These IHC high
samples were further analysed with SISH. This algorithm
is based on our previous observation that high EGFR IHC
staining intensity positively correlates with increased
EGFR GCN [7]. With HER2 IHC, tumours were scored
according to standard criteria [11, 12] and specimens
showing 2+ or 3+ membranous staining in ≥10 % of
tumour cells or in ≥5 clustered tumour cells in biopsies
were classified as IHC high and analysed with SISH. EGFR
and HER2 IHC and GCN were scored independently by
two observers (EB and JS) without knowledge of the clin-
ical information. Consensus scoring was used in case of
differing individual results.
EGFR was quantified from the areas of high EGFR
IHC intensity as described previously [7, 8]. Forty
tumour cells with the highest number of copies were
analysed from the EGFR SISH slides and an average
value was calculated for each surgical sample. If these
forty cells contained numerous overlapping EGFR SISH
signals (clusters), the tumour was determined to have
EGFR gene amplification. In biopsies, a group of ≥5
tumours cells with gene clusters was considered as
amplification. One EGFR cluster was approximated to
contain ≥10 gene copies. HER2 GCN was detected with
chromosome 17 (Chr-17) number (number of copies of
chromosome per cell) and the HER2/Chr-17 ratio was
assessed according to standard criteria [13]. If HER2 gene
clusters were detected in ≥10 % of tumour cells in surgical
specimens or in a group of ≥5 tumour cells in biopsies,
the tumour was determined to contain HER2 gene
amplification. One HER2 cluster was counted as ≥6
gene copies. To validate our method of including only
tumours with high EGFR IHC intensity for EGFR SISH,
we assessed EGFR GCN in fifteen randomly selected
tumours in which EGFR IHC was scored as negative/
weak. No EGFR amplification was found in these tumours
(GCN 2.1–3.3).
Statistical analysis
Statistical analyses were performed with IBM SPSS
Statistics for Windows, version 21.0 (IBM Corporation,
Armonk, NY). Frequency table data were analysed using
the χ2 test, either with the Pearson χ2 test or Fisher’s exact
test for categorical variables. 2 × 2 tables were used to
calculate odds ratios (OR). Kaplan-Meier method and
log-rank test as well as Cox’s proportional hazards re-
gression model were used for univariate survival ana-
lysis. Multivariate survival analysis was performed by
Cox’s proportional hazards regression model. Variables
with a p-value under 0.2 in univariate analysis were in-
cluded in the multivariate analyses. Time to recurrence
(TTR) was calculated from the time of diagnosis to the
time of first recurrence, death of primary cancer or to the
last follow-up date. Only recurrences occurring ≥6 months
after diagnosis were considered relevant. Earlier detection
of a local or distant recurrence was considered likely to
present an initially advanced disease. Patients treated with
surgery or surgery and adjuvant therapy without disease
recurrence ≥6 months after diagnosis were considered
curatively treated. Cancer-specific survival (CSS) was
calculated from the time of diagnosis to the time of
death of primary cancer or the last follow-up date and
overall survival (OS) from the time of diagnosis to the
time of death of any cause or the last follow-up date.
Five patients (2.3 %) who had received trastuzumab
treatment for recurrent cancer were excluded from the
CSS and OS analyses and additionally 14 patients with
stage IV disease (6.4 %) from the TTR analysis. All stat-
istical tests were two-sided and p-values under 0.05
were considered statistically significant.
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Results
EGFR and HER2 immunohistochemical staining
All 220 tumour samples were analysed with EGFR and
HER2 IHC. High membranous or membranous + cyto-
plasmic EGFR IHC staining intensity (2+/3+) was ob-
served in 72 (32.7 %) of the tumours, while 2+/3+ HER2
IHC staining intensity was present in 31 (14.1 %) tumours.
Among these, concurrent high IHC staining intensity of
EGFR and HER2 was detected in 14 (6.4 %) tumours. The
results from EGFR and HER2 IHC stainings are shown in
Table 2.
EGFR and HER2 silver in situ hybridisation
Gene copy numbers were analysed with EGFR or HER2
SISH in all tumours with high EGFR or HER2 IHC
staining intensity. EGFR gene amplification was found in
31/72 tumours (14.1 % of the whole study material) and
HER2 gene amplification in 29/31 tumours (13.2 % of
the whole study material). Among these, EGFR and
HER2 co-amplification was detected in 8/14 tumours
(3.6 % of the whole study material). EGFR and HER2
gene amplification status was significantly concordant in
antrum (Fisher’s exact test, p = 0.004). The results from
EGFR and HER2 SISH stainings according to anatomical
location are presented in Table 3. There was marked
intratumoural heterogeneity of EGFR and HER2 gene
amplification, as shown in Figs. 1 and 2.
EGFR and HER2 protein expression and gene
amplification in relation to clinicopathological variables
Evaluated by IHC staining intensity, moderate or strong
EGFR protein expression was associated with the depth
of tumour invasion (pT3–pT4 versus pT1–pT2; Fisher’s
exact test, p = 0.029); OR 2.15, 95 % CI: 1.11–4.17), but
did not associate with tumour location (distal oesophagus/
GOJ/cardia versus gastric corpus/antrum/pylorus; Fisher’s
exact test, p = 0.054). In contrast, no significant association
was found between HER2 protein expression levels and
the depth of tumour invasion or tumour location. No sig-
nificant association was observed between EGFR or HER2
protein expression levels and patient gender, tumour stage
or histological differentiation grade.
EGFR gene amplification was associated with deep in-
vasion (pT3–pT4 versus pT1–pT2; Fisher’s exact test,
p = 0.020; OR 3.49, 95 % CI: 1.17–10.4) and it was more
commonly detected in stage III–IV tumours than in
stage I–II tumours (Fisher’s exact test, p = 0.024; OR
2.55, 95 % CI: 1.18–5.51). Additionally, EGFR gene
amplification was more common in tumours of distal
oesophagus (5/20 tumours, 25.0 %) and GOJ/cardia
(13/63 tumours, 20.6 %) than in those of gastric corpus
(2/65 tumours, 3.1 %) (χ2, p = 0.013). This distribution
pattern was also seen in male patients (χ2, p = 0.034)
but not in female patients. When tumour location was
considered as a dichotomous variable, EGFR gene amp-
lification was still more common in proximally located
tumours (distal oesophagus/GOJ/cardia versus gastric
corpus/antrum/pylorus; (Fisher’s exact test, p = 0.016);
OR 2.64, 95 % CI: 1.22–5.73). When analysed separately
for males and females, the association between EGFR
gene amplification and proximal tumours was signifi-
cant in males (Fisher’s exact test, p = 0.011; OR 3.58,
95 % CI: 1.37–9.36) but not in females. In contrast,
HER2 gene amplification status was not significantly
associated with the depth of tumour invasion, tumour
stage or tumour location. No significant association
was found between EGFR or HER2 gene amplification
status and patient gender, age at diagnosis or histological
differentiation grade of the tumour. The association be-
tween EGFR and HER2 protein expression as well as gene
amplification and different clinicopathological variables
are presented in Table 4.
EGFR and HER2 gene amplification in relation to survival
In univariate survival analysis, EGFR gene amplification
was associated with shortened time to recurrence (TTR,
median) (22 vs. 57 months, log-rank test, p = 0.026; Cox
test, p = 0.028, HR: 1.73, 95 % CI: 1.06–2.83) and with
shortened cancer-specific survival (CSS, median) (29 vs.
57 months, log-rank test, p = 0.033; Cox test, p = 0.035,
HR: 1.67, 95 % CI: 1.04–2.69) (Fig. 3). Median TTR and
CSS of the patients were both 45 months. HER2 gene
amplification was not significantly associated with TTR,
but patients with HER2 gene amplification had a notably
lower median CSS of 22 months than patients without
HER2 amplification (46 months). However, the differ-
ence was not statistically significant (log-rank test, p =
0.256) (Fig. 3).
In univariate analysis, increasing depth of tumour in-
vasion was associated with decreased TTR and CSS
Table 2 Intensity of EGFR and HER2 immunohistochemical stainings in intestinal adenocarcinomasa (N = 220)
IHC staining intensity EGFR, N (%)a HER2, N (%)b EGFR and HER2, N (%)c
0/1+ 148 (67.3) 189 (85.9) 131 (59.5)
2+/3+ 72 (32.7) 31 (14.1) 14 (6.4)
IHC immunohistochemistry. 0, negative; 1+ low; 2+ moderate; 3+ strong
aAccording to the most intense membranous or membranous + cytoplasmic staining
bAccording to the most intense membranous staining
cConcordant IHC staining intensity. In 75 tumours (34.1 %) IHC staining intensity was discordant
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(TTR: log-rank test, p < 0.0001; Cox test, p < 0.0001, HR
1.46, 95 % CI: 1.19–1.80 and CSS: log-rank test, p <
0.0001; Cox test, p < 0.0001, HR 1.60, 95 % CI: 1.30–1.96).
Similarly, increasing tumour stage was associated with de-
creased TTR and CSS (TTR: log-rank test, p = 0.005; Cox
test, p = 0.001, HR 1.52, 95 % CI: 1.18–1.96 and CSS: log-
rank test, p < 0.0001; Cox test p < 0.0001, HR 1.94, 95 %
CI: 1.53–2.45). In addition, increasing patient age at the
time of diagnosis was associated with shorter CSS (Cox
test, p = 0.048, HR 1.02, 95 % CI: 1.00 − 1.04), but not with
TTR (Cox test, p = 0.341). No significant association
was found between patient gender (log-rank test, TTR:
p = 0.372; CSS: p = 0.818) or tumour location (log-rank
test, TTR: p = 0.057; CSS: p = 0.262). In Kaplan-Meier
analysis, histological differentiation grade was not associ-
ated with survival (grade I versus II versus III; log-rank
test, TTR: p = 0.118; CSS: p = 0.053). However, when ana-
lysed separately grade II tumours were associated with
shorter TTR in comparison to grade I tumours (univariate
Cox test, p = 0.043, HR 1.95, 95 % CI: 1.02–3.74). Add-
itionally, grade II and III tumours were associated with
shorter CSS in comparison to grade I tumours (univariate
Cox test, grade II: p = 0.020, HR 2.22, 95 % CI: 1.13–4.36;
grade III: p = 0.029, HR 2.15, 95 % CI: 1.08–4.27). No
significant association was observed between EGFR or
HER2 gene amplification status and overall survival
(OS). EGFR or HER2 protein expression, evaluated by
IHC staining intensity, was not significantly associated
with TTR, CSS or OS.
In the multivariate model for TTR, EGFR gene amplifica-
tion was analysed together with tumour stage, histological
differentiation grade and tumour location. In the multivari-
ate analysis for CSS, EGFR gene amplification was analysed
together with tumour stage, histological differentiation
grade and patient age at the time of diagnosis. Tumour
stage remained as a single predictive factor for TTR
(Cox test, stage III: p = 0.014, HR 2.05, 95 % CI: 1.16–3.63)
as well as for CSS (Cox test, stage III: p = 0.023, HR 1.99,
95 % CI: 1.10–3.61; stage IV: p < 0.0001, HR 11.4, 95 % CI:
5.34–24.4). The results from univariate and multivariate
survival analyses are presented in Table 5.
Discussion
This study shows that EGFR gene amplification is not
uncommon in intestinal adenocarcinoma of the stom-
ach, gastro-oesophageal junction and distal oesophagus.
In addition, we demonstrate that EGFR amplification is
most prevalent in proximally located tumours and sig-
nificantly associated with decreased survival, as defined
by TTR and CSS.
In previous studies, EGFR gene amplification has been
reported to be present in only 2.3–4.9 % of gastric can-
cers including all histological subtypes [14–16], whereas
the reported numbers for HER2 gene amplification vary
between 7 and 17 % [17, 18]. The prevalence of EGFR
and HER2 co-amplification has been reported as low
(<0.5 %) [15, 16], albeit studies analysing concurrent
EGFR and HER2 GCN changes are few and none have
been carried out after the novel molecular subtypes of
gastric cancer were published [2]. In contrast, we found
EGFR gene amplification in 14.4 % and receptor co-
amplification in 3.6 % of intestinal adenocarcinomas.
Table 3 EGFR and HER2 silver in situ hybridization in intestinal-type adenocarcinomas according to anatomical location
Gene copy number status Distal oesophagus GOJ/cardia Corpus Antrum/pylorus Total P value
N = 20 (%) N = 63 (%) N = 65 (%) N = 72 (%) N = 220 (%) (χ2 test)c
EGFR amplificationa
Yes 5 (16.1) 13 (41.9) 2 (6.5) 11 (35.5) 31 (100.0) 0.013d
No 15 (7.9) 50 (26.5) 63 (33.3) 61 (32.3) 189 (100.0)
Total N of amplification (%) 5/20 (25.0) 13/63 (20.6) 2/65 (3.1) 11/72 (15.3) 31/220 (14.1)
HER2 amplificationa
Yes 5 (17.2) 9 (31.0) 9 (31.0) 6 (20.7) 29 (100.0) NS
No 15 (7.9) 54 (28.3) 56 (29.3) 66 (34.6) 191 (100.0)
Total N of amplification (%) 5/20 (25.0) 9/63 (14.3) 9/65 (13.8) 6/72 (8.3) 29/220 (13.2)
EGFR and HER2 co-amplificationa
Yes 2 (25.0) 1 (12.5) 1 (12.5) 4 (50.0) 8 (100.0) NS
No 18 (8.5) 62 (29.2) 64 (30.2) 68 (32.1) 212 (100.0)
Total N of co-amplification (%) 2/20 (10.0) 1/63 (1.6) 1/65 (1.5) 4/72 (5.6) 8/220 (3.6)
P value (Fisher’s exact test)b NS NS NS 0.004d
IHC immunohistochemistry, GOJ gastro-oesophageal junction, GCN gene copy number, NS not significant
aAmplification, GCN >10 for EGFR; GCN >6 for HER2
bConcordant vs. discordant EGFR and HER2 amplification status
cDistal oesophagus, GOJ and cardia vs. corpus
dStatistically significant
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HER2 has been found to be overexpressed, as determined
by both IHC and GCN analyses, in 7–25 % of gastric
adenocarcinomas [11, 12, 17, 19] including all histological
subtypes, which is comparable with our finding that high
HER2 protein expression was found in 14.1 % and HER2
gene amplification in 13.2 % of intestinal adenocarcinomas.
Recent molecular classification studies have linked
approximately 36–50 % of gastric adenocarcinomas
Fig. 1 The association between EGFR/HER2 protein expression and EGFR/HER2 gene amplification in two intestinal-type oesophagogastric
adenocarcinomas. Figures a–d show the same area in a single tumour: a Strong (3+) membranous EGFR protein expression (IHC), b negative HER2
protein expression and c–d EGFR gene amplification (SISH). Figures e–h show the same area in another tumour: e Negative EGFR protein expression
(IHC), (f) strong (3+) membranous HER2 protein expression and g–h HER2 gene amplification (SISH). Original objective magnification 10x and 60x. IHC,
immunohistochemistry; SISH, silver in situ hybridisation
Birkman et al. BMC Cancer  (2016) 16:406 Page 7 of 14
with characteristics such as intestinal-type histology,
chromosomal abnormalities, changes in the receptor
tyrosine kinase–RAS signaling pathway, as well as TP53
gene and somatic copy-number aberrations. These
characteristics have been associated with a distinct mo-
lecular subgroup: tumours in the CIN subgroup are
characterised by chromosomal instability, while the
MSS/TP53− subgroup typically contains microsatellite
stable tumours with inactive TP53 [2, 20]. Both of these
studies could further show that histologically diffuse-
type tumours are concentrated in a separate subgroup
with molecular characteristics different from those de-
fining CIN or MSS/TP53−. However, the predominant
anatomical location of tumours belonging to either
CIN or MSS/TP53− subgroup was found to differ: CIN
tumours were mostly located in GOJ/cardia, whereas
MSS/TP53− tumours were predominantly situated in
gastric antrum [2, 20]. It has been previously demon-
strated that HER2 gene amplification is strongly associated
with the intestinal histological subtype, as compared to
the diffuse subtype, as well as with the gastro-oesophageal
location of tumours [17, 19]. In our material, EGFR gene
amplification was most common in the tumours of distal
oesophagus and GOJ/cardia, as observed in the CIN
subgroup, but infrequent in the tumours of gastric cor-
pus. In antral/pyloric tumours, the observed prevalence
of EGFR gene amplification was intermediate to that in
other locations.
EGFR gene amplification was found to be significantly
associated with decreased TTR and CSS, which is con-
sistent with earlier findings of association between EGFR
gene amplification and survival [14, 15]. Results from
these studies are, however, based on notably smaller
sample size and/or histologically more heterogeneous
tumour material than included in this present study.
There are contradictory reports regarding the relevance
of HER2 gene amplification as a negative prognostic factor
in gastric cancer [15, 17]. In this study, the non-significant
association may partly be related to including only intes-
tinal adenocarcinomas in the study material.
HER2 overexpression is known to predict treatment
benefit from anti-HER2 antibody therapy. The survival
of patients is significantly improved in metastatic gastric
and gastro-oesophageal cancer by the addition of trastuzu-
mab to a cisplatin-fluoropyrimidine-containing chemother-
apy regimen [12], whereas no survival benefit has been
Fig. 2 The association between strong EGFR/HER2 protein expression and EGFR/HER2 gene amplification in a single intestinal-type oesophagogastric
adenocarcinoma (original objective magnification 10x). All images are from the same area of the tumour. a Strong (3+) EGFR protein expression (IHC).
b EGFR gene amplification (SISH). c Strong (3+) HER2 protein expression (IHC). d HER2 gene amplification (SISH). Insets show the gene
amplification (original objective magnification 60x). Note that EGFR and HER2 are not amplified in the same cancer cells but in adjacent
areas. IHC, immunohistochemistry; SISH, silver in situ hybridisation
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Table 4 Association between the clinicopathological variables and EGFR/HER2 protein expression or gene amplification (N = 220)
EGFR IHC staining intensity, N (%) EGFR in situ hybridisation status, N (%) HER2 IHC staining intensity, N (%) HER2 in situ hybridisation status, N (%)










Female 59 (39.9) 20 (27.8) NS 8 (25.8) 71 (37.6) NS 69 (36.5) 10 (32.3) NS 8 (27.6) 71 (37.2) NS
Male 89 (60.1) 52 (72.2) 23 (74.2) 118 (62.4) 120 (63.5) 21 (67.7) 21 (72.4) 120 (62.8)
Site of primary tumour
Distal oesophagus/
GOJ/cardia
49 (33.1) 34 (47.2) NS 18 (58.1) 65 (34.4) 0.016 69 (36.5) 14 (45.2) NS 14 (48.3) 69 (36.1) NS
Corpus/antrum/
pylorus
99 (66.9) 38 (52.8) 13 (41.9) 124 (65.6) 120 (63.5) 17 (54.8) 15 (51.7) 122 (63.9)
Histological differentiation grade
Grade I 23 (15.5) 7 (9.7) NS 2 (6.5) 28 (14.8) NS 28 (14.8) 2 (6.5) NS 2 (6.9) 28 (14.7) NS
Grade II 71 (48.0) 32 (44.4) 17 (54.8) 86 (45.5) 83 (43.9) 20 (64.5) 18 (62.1) 85 (44.5)
Grade III 54 (36.5) 33 (45.8) 12 (38.7) 75 (39.7) 78 (41.3) 9 (29.0) 9 (31.0) 78 (40.8)
Postoperative Tb
pT1–pT2 54 (37.0) 15 (21.4) 0.029 4 (13.31) 65 (34.9) 0.020 63 (34.1) 6 (19.4) NS 6 (20.7) 63 (33.7) NS
pT3–pT4 92 (63.0) 55 (78.6) 26 (86.7) 121 (65.1) 122 (65.9) 25 (80.6) 23 (79.3) 124 (66.3)
Postoperative stage
I–II 100 (67.6) 42 (58.3) NS 14 (45.2) 128 (67.7) 0.024 125 (66.1) 17 (54.8) NS 15 (51.7) 127 (66.5) NS
III–IV 48 (32.4) 30 (41.7) 17 (54.8) 61 (32.3) 64 (33.9) 14 (45.2) 14 (48.3) 64 (33.5)
aFisher’s exact test












demonstrated in phase III clinical trials with anti-EGFR
antibody treatment in comparison to other chemotherapeu-
tic regimens [5, 6]. While the EGFR status was not used for
patient selection in these earlier studies, an ongoing phase
III clinical trial has been reported to select patients based
on EGFR overexpression, although defined only by IHC
[21]. Overexpression of EGFR protein has been reported in
24–27 % of all gastric adenocarcinomas [14, 16] and in
31 % [14] of intestinal gastric adenocarcinomas. In our
study, we found that 32.7 % of the intestinal adenocarcin-
omas had high EGFR IHC staining intensity, but only 31/
72 (43.1 %) of these demonstrated EGFR gene amplifica-
tion. This suggests that determining EGFR overexpression
of tumours only by IHC, without knowledge of the EGFR
GCN, may be an inadequate method for selecting patients
for anti-EGFR therapy. Indeed, a recent preclinical study
with patient derived xenografts indicated that strongest re-
sponse to anti-EGFR therapy was achieved in tumours with
Fig. 3 Kaplan-Meier survival curves of intestinal-type oesophagogastric cancer patients with or without EGFR or HER2 amplification. Time to recurrence
(a–b) and cancer-specific survival (c–d) as based on EGFR (a, c) and HER2 (b, d) SISH and IHC analyses. IHC, immunohistochemistry; SISH, silver
in situ hybridisation
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Table 5 Time to recurrence (TTR)a and cancer-specific survival (CSS)b of patients with intestinal-type adenocarcinomas
Univariate survival analysis for TTR Multivariate survival
analysis for TTR













HR 95 % CI P value,
Cox testb











HR 95 % CI P value,
Cox testb
HR 95 % CI
Age (continuous variable) 198 NS 212 0.048 1.02 1.00–1.04 NS
Patient gender
Female (reference) 71 56.6 NS NS 78 45.6 NS NS
Male 127 38.2 134 44.6




75 28.5 NS NS 77 34.3 NS
Corpus/antrum/
pylorus
123 53.6 NS 135 47.1 NS
Histological differentiation grade
Grade I (reference) 30 NA NS 30 NA NS
Grade II 92 33.8 0.043 1.95 1.02–3.74 NS 98 33.8 0.020 2.22 1.13–4.36 NS
Grade III 76 53.2 NS NS 84 44.6 0.029 2.15 1.08–4.27 NS
Postoperative T
pT1 (reference) 37 67.3 <0.0001 37 NA <0.0001
pT2 31 NA NS 31 NA NS
pT3 75 56.6 NS 82 57.3 NS
pT4 55 20.5 0.002 2.59 1.44–4.67 59 25.7 0.001 2.94 1.58–5.47
Postoperative stage
I (reference) 58 NA 0.005 58 NA <0.0001
II 80 38.2 NS NS 80 57.3 NS NS
III 60 22.6 0.001 2.33 1.38–3.92 0.014 2.05 1.16–3.63 60 29.0 0.002 2.36 1.37–4.08 0.023 1.99 1.10–3.61
IV NA 14 6.90 <0.0001 14.2 6.86–29.3 <0.0001 11.4 5.34–24.4
EGFR amplification
Yes 28 21.8 0.026 0.028 1.73 1.06–2.83 NS 30 29.0 0.033 0.035 1.67 1.04–2.69 NS












Table 5 Time to recurrence (TTR)a and cancer-specific survival (CSS)b of patients with intestinal-type adenocarcinomas (Continued)
HER2 amplification
Yes 20 44.6 NS NS 25 22.3 NS NS
No (reference) 178 45.6 187 45.6
NS not significant, NA not applicable
aExcluding trastuzumab-treated and stage IV patients
bExcluding trastuzumab-treated patients
cKaplan-Meier method












EGFR gene amplification [22]. The relatively low prevalence
of co-amplification of EGFR and HER2 genes (3.6 % in this
study) demonstrates the presence of two distinct subgroups
of patients with either EGFR or HER2 gene amplification,
which implies that anti-EGFR therapies might be applicable
to some patients not eligible for anti-HER2 treatment.
Those patients having receptor co-amplification might even
benefit from a dual-acting antibody treatment.
Conclusions
In this study, we have shown that EGFR gene amplifica-
tion is relatively common in intestinal adenocarcinomas
of the stomach, gastro-oesophageal junction and distal
oesophagus and associates with decreased survival. We
have also demonstrated that EGFR GCN can be easily
analysed by silver in situ hybridisation in diagnostic
tumour material and thus could be applied as a routine
histopathological diagnostic method. Based on our re-
sults, we suggest that determining EGFR gene amplifica-
tion status in concert with IHC could be used in future
clinical trials to identify patients with inverse prognosis
and to improve the specificity of patient selection when
investigating the possible benefits of anti-EGFR therapies
in the treatment of intestinal-type gastro-oesophageal
adenocarcinomas.
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